In a report issued on December 27, Jason Kolbert from Dawson James maintained a Buy rating on Collplant Holdings (CLGN – Research Report), with a price target of $20.00. The company’s shares closed last Thursday at $13.82.
According to TipRanks.com, Kolbert is a 4-star analyst with an average return of 5.0% and a 41.9% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics.
Currently, the analyst consensus on Collplant Holdings is a Moderate Buy with an average price target of $20.00.
Based on Collplant Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $140K and GAAP net loss of $3.08 million. In comparison, last year the company earned revenue of $4.15 million and had a net profit of $703K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CollPlant Biotechnologies Ltd. is a regenerative medicine company. It engages in the research, development, manufacture and marketing of medical products for tissue repair, initially for orthobiologics and advanced wound care markets. The company’s products include VergenixSTR, VergenixFG, CollPlant Surgical Matrix. Collplant Holdings was founded by in June 2004 and is headquartered in Ness-Ziona, Israel.
Read More on CLGN:
- Dawson James Sticks to Their Buy Rating for Daré Bioscience (DARE)
- Dawson James Remains a Buy on Daré Bioscience (DARE)
- Dawson James Reaffirms Their Buy Rating on SRAX (SRAX)
- Analysts’ Top Conglomerates Picks: Flughafen Zurich AG (UZAPF)
- Analysts Offer Insights on Consumer Goods Companies: Chewy (CHWY) and Columbia Care (OtherCCHWF)